Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics showcased three notable ePosters at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) focused on its investigational drug, ridinilazole, for treating Clostridioides difficile infections. Key findings include ridinilazole's ability to preserve gut microbiota without increasing antibiotic resistance, and its novel mechanism of action targeting C. difficile DNA. Amid two pivotal Phase III trials, these results reinforce ridinilazole's potential as a first-line treatment, minimizing disease recurrence and aligning with regulatory efforts for its approval.
Summit Therapeutics (NASDAQ: SMMT) announced that its scientific team will present significant research at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from July 9-12, 2021. Highlights include a Top Rated ePoster on the impact of the antibiotic Ridinilazole on gut microbiota. Ridinilazole is in Phase III trials aimed at treating and preventing recurrence of Clostridioides difficile infection (CDI), a serious illness affecting over 500,000 annual cases in the U.S. The company aims to provide effective therapies with minimal side effects.
Summit Therapeutics Inc. (NASDAQ: SMMT) will join the Russell 3000® Index after the annual reconstitution on June 28, 2021. This addition, determined by market capitalization, signifies recognition of the company's progress in addressing unmet medical needs. The Russell 3000® Index, encompassing 4,000 large U.S. stocks, facilitates investment strategies for managers, with over $10.6 trillion benchmarks tied to it. Summit Therapeutics aims to lead in treatments for infectious diseases, focusing on novel antibiotics aligned with the human microbiome.
Summit Therapeutics Inc. (NASDAQ: SMMT) is set to hold its virtual Annual Shareholders’ Meeting on June 16, 2021, at 1:00 pm ET. Shareholders and interested parties are invited to attend through a provided online link. The company's innovative Discuva Platform aims to advance treatments for infectious diseases, focusing on Clostridioides difficile infections. Summit's lead candidate, ridinilazole, is currently in pivotal Phase 3 trials, while SMT-738 is in the IND-enabling phase for multidrug-resistant infections. Regulatory approvals are essential for commercialization.
Summit Therapeutics (NASDAQ: SMMT) has selected SMT026738, a new preclinical candidate targeting multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae (CRE). The company received an initial award of up to $4.1 million from CARB-X to advance SMT-738 through preclinical and Phase 1a trials, with potential additional funding of $3.7 million based on milestones. SMT-738 employs a novel mechanism using LolCDE, targeting pathogens like Escherichia coli and Klebsiella pneumoniae, offering hope against infections with limited treatment options due to antibiotic resistance.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its Q1 2021 financial results, highlighting significant developments in its clinical trials and financial standing. The company has enrolled 652 patients in its ridinilazole Phase 3 trials, with a goal of 1,360. Financially, cash and cash equivalents rose to $102.2 million, up from $66.4 million at the end of 2020, bolstered by a $75 million Rights Offering. However, the company posted a net loss of $17.5 million for Q1 2021, significantly higher than the $6.1 million loss in Q1 2020.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced the successful closing of its rights offering, raising $75 million from the sale of 14,312,976 shares at $5.24 each. The offering incurred approximately $200,000 in expenses, resulting in net proceeds of $74.8 million. Following this issuance, the total shares outstanding is 97,244,567. CEO Mr. Duggan emphasized the offering allowed all stockholders to participate based on their ownership. Unexercised subscription rights expired on May 10, 2021.
Summary not available.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced an impending expiration of its rights offering at 5:00 PM EDT on May 10, 2021. Shareholders must act quickly, as brokerage deadlines may begin today, May 5. The offering entails up to 14,312,977 shares with a total value of up to $75 million. The subscription price will be the lower of $5.24 or the volume-weighted average price over the last ten trading days. Notably, CEO Robert Duggan plans to exercise both his basic and oversubscription rights.
Summit Therapeutics announces a rights offering to raise up to $75 million by issuing 14,312,977 shares of common stock. The offering, effective April 21, 2021, allows existing stockholders, as of April 9, 2021, to purchase shares at $5.24 each or at a lower volume-weighted average price if applicable. Subscription rights must be exercised by May 10, 2021. Non-transferable rights will have no value if not exercised before the expiration date. Further details can be found in the prospectus filed with the SEC.